SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-116331
Filing Date
2022-04-25
Accepted
2022-04-25 07:31:31
Documents
14
Period of Report
2022-04-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d203945d8k.htm   iXBRL 8-K 24727
2 EX-99.1 d203945dex991.htm EX-99.1 13893
6 GRAPHIC g203945g0425002359252.jpg GRAPHIC 3070
  Complete submission text file 0001193125-22-116331.txt   170822

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA arwr-20220425.xsd EX-101.SCH 2888
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20220425_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20220425_pre.xml EX-101.PRE 11283
8 EXTRACTED XBRL INSTANCE DOCUMENT d203945d8k_htm.xml XML 3361
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

IRS No.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 22847329
SIC: 2834 Pharmaceutical Preparations